Potential hidden *Plasmodium vivax* malaria reservoirs from low parasitemia Duffy-negative Ethiopians: molecular evidence

3

Abnet Abebe^{1,2*}, Isabelle Bouyssou^{3,4}, Solenne Mabilotte⁵, Sisay Dugassa¹, Ashenafi Assefa^{2,6},
Jonathan J. Juliano⁷, Eugenia Lo⁸, Didier Menard^{3,5,9,10}, Lemu Golassa^{1*}

- 6
- 7

8 Affiliations

- 9 ¹Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Ethiopia.
- 10 ² Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
- ³ Institut Pasteur, Université Paris Cité, Malaria Genetics and Resistance Unit, INSERM U1201, F-75015
 Paris, France.
- ⁴ Sorbonne Université, Collège Doctoral ED 515 Complexité du Vivant, F-75015 Paris, France.
- ⁵ Université de Strasbourg, Institute of Parasitology and Tropical Diseases, UR7292 Dynamics of Host-
- 15 Pathogen Interactions, F-67000 Strasbourg, France.
- ⁶ Institute of Infectious Disease and Global Health, University of North Carolina at Chapel Hill, Chapel
- 17 Hill, NC, USA.
- ⁷ Division of Infectious Disease, School of Medicine, University of North Carolina at Chapel Hill, Chapel
- 19 Hill, NC, USA.
- 20 ⁸ Department of Biological Sciences, Bioinformatics Research Center, University of North Carolina at
- 21 Charlotte, USA.
- ⁹ Institut Pasteur, Université Paris Cité, Malaria Parasite Biology and Vaccines Unit, F-75015 Paris,
 France.
- 24 ¹⁰ CHU Strasbourg, Laboratory of Parasitology and Medical Mycology, F-67000 Strasbourg,
- 25 France
- 26
- 27

28 *Corresponding authors; E-mail:

- 29 Abnet Abebe: <u>abnetabas@gmail.com</u>
- 30 Phone: +251911701745; P.O. Box 24756; Addis Ababa, Ethiopia
- 31 Lemu Golassa : lgolassa@gmail.com
- **32** Phone: +251911371981

- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42 43

44 Abstract

Background: The interaction between the *Plasmodium vivax* Duffy-binding protein and the corresponding Duffy Antigen Receptor for Chemokines (DARC) is primarily responsible for the invasion of reticulocytes by *P. vivax*. The Duffy-negative host phenotype, highly prevalent in sub-Saharan Africa, is caused by a single point mutation in the GATA-1 transcription factor binding site of the DARC gene promoter. The aim of this study was to assess the Duffy status of patients with *P. vivax* infection from different study sites in Ethiopia.

51 **Methods:** A cross-sectional study was conducted from February 2021 to September 2022 at five 52 varying eco-epidemiological malaria endemic sites in Ethiopia. Outpatients who were diagnosed 53 with *P. vivax* infection (pure and mixed *P. vivax/P. falciparum*) by microscopy were subjected to 54 qPCR genotyping at the DARC promoter. The associations between *P. vivax* infection, host 55 genotypes and other factors were evaluated.

Result: In total, 361 patients with *P. vivax* infection were included in the study. Patients with 56 57 pure P. vivax infections accounted for 89.8% (324/361), while the remaining 10.2% (37/361) had mixed P. vivax/P. falciparum infections. About 95.6% (345/361) of the participants were Duffy-58 positives (21.2% homozygous and 78.8%, heterozygous) and 4.4% (16/361) were Duffy-59 negatives. The mean asexual parasite density in homozygous and heterozygous Duffy-positives 60 was 12,165 p/µl (IQR25-75: 1,640-24,234 p/µl) and11,655 p/µl (IQR25-75: 1,676-14,065 p/µl), 61 respectively, significantly higher than that in Duffy-negatives (1,227p/µl; IQR25-75: 539-62 $1,732p/\mu l$). 63

64 **Conclusion:** This study confirms that Duffy-negativity does not provide complete protection 65 against *P. vivax* infection. The development of *P. vivax*-specific elimination strategies, including 66 alternative antimalarial vaccines should be facilitated by a better understanding of the

67	epidemiological landscape of vivax malaria in Africa. More importantly, low parasitemia
68	associated with P. vivax infections in Duffy-negative patients may represent hidden reservoirs of
69	transmission in Ethiopia.
70	
71	Key Words: Plasmodium vivax, Duffy, heterozygous, homozygous, malaria, Ethiopia
72	
73	
74 75	Author Summary
76	Plasmodium vivax generally receives less attention than P. falciparum and was neglected in sub-
77	Saharan Africa. However, the characteristics of <i>P. vivax</i> infection in Duffy-negative individuals,
78	and the distribution of Duffy blood group in different eco-epidemiological zones and ethnic
79	groups of Ethiopia are not well documented. Here, we determined the Duffy genotypes of P.
80	vivax infected patients across broad regions of Ethiopia. It is clear that Duffy negative
81	individuals in Ethiopia are not fully protected against P. vivax infection, and that these infections
82	in Duffy negatives are often associated with low parasitemia. Our findings lend support to the
83	notion that P. vivax may have developed a Duffy-independent erythrocyte invasion pathway
84	and/or evolution in host immune responses.
85	
86	
87	
88	
89	
90	

91 Introduction

92

In 2021, there were an estimated 247 million cases and 619,000 deaths from malaria worldwide.

- 94 Of these, 2% of the cases were due to *P. vivax*, mainly in the Horn of Africa, South America,
- 95 India and Asia (1). *P. vivax* malaria is recognized as a cause of severe morbidity and mortality,
- 96 with a significant negative impact on health in endemic countries (2–4). The unique biological
- 97 features of *P. vivax*, such as hypnozoite formation and early gametocytogenesis, pose a challenge
- 98 to global malaria elimination efforts (5).
- 99 The *P. vivax* invasion pathway into reticulocytes was previously thought to be primarily
- dependent on the interaction between the Duffy binding protein (PvDBP) and its cognate
- 101 receptor, the Duffy Antigen Receptor for Chemokines (DARC) (6–8). Polymorphisms in the

promoter of the *DARC* gene alter the expression of the Duffy antigen protein and determine an

- 103 individual's Duffy blood group (9). A point mutation in the GATA-1 transcription factor binding
- site of the promoter of the gene at position–67 encodes the change of a T nucleotide to a C
- nucleotide and underlies the Duffy-negative (erythrocyte silent) phenotype (10–12). Individuals
- 106 with this mutation do not express the Duffy antigen on the surface of their erythrocytes (13).
- 107 Duffy-negative phenotype in the population occurs at low frequency in Caucasians (\sim 3.5%) (14),
- and has a prevalence of almost 100% in West Africa, > 80% in African Americans (15), 20-36%
- in East Africa and 84% in southern Africa (16). In Ethiopia, a study reported 94/416 (~23%) of
- the febrile patients from the six health centres/hospitals were Duffy-negatives, though only two
- 111 of them were confirmed with *P. vivax* (17).

112 The scientific paradigm that *P. vivax* exclusively invades Duffy-positive reticulocytes through 113 the interactions of PvDBP and *DARC* was established, and it was assumed that *vivax* malaria was 114 rarely transmitted or even absent in regions where Duffy-negativity predominates, such as sub-

115 Saharan Africa (18,19). However, recent studies have shown that <i>P. vivax</i> can in	ect Duffy-
--	------------

- negative reticulocytes (20), and is no longer a barrier to such infections (21). In East Africa, the
- prevalence of *P. vivax* in Duffy-negative populations ranges from 3% (22) to ~12% in
- Ethiopia(16) and 3%(16) to $\sim 18\%$ in Sudan (9). Although several studies have demonstrated the
- 119 presence of *P. vivax* infection in Duffy-negative individuals, the distribution of these infections
- in different eco-epidemiological zones and ethnic groups are not well documented, especially in
- 121 Ethiopia. This study compares the prevalence of Duffy blood group genotypes of *P. vivax*
- infected patients among different eco-epidemiological zones of Ethiopia.
- 123

124 Materials and Methods

125 Study design, period and areas

A health-facility based cross-sectional study was conducted from February 2021 to September
2022. Based on the annual parasite index (API), malaria risk stratification in Ethiopia is divided
into five classes: i) malaria free, ii) very low, iii) low, iv) moderate and v) high malaria risk.
The study sites were selected from different malaria risk stratification areas. The sites include:
Arbaminch, Dubti, Gambella, Metehara, and Shewarobit (*Figure 1*). Arbaminch hospital is
located in the Southern Nation and Nationalities People Regional State in the southern part of the
country (altitude 1200 m; Lat, Long: 6.02043, 37.56788); Dubti hospital is located in the Afar

133 Regional State in the northern-east part of the country (altitude 379 m; Lat, Long: 11.72654,

134 41.09440); Gambella hospital is located in Gambella Regional State in the western part of the

- 135 country (altitude 447 m; Lat, Long: 8.24810, 34.59071); Metehara hospital is located in Oromia
- 136 Regional State in the eastern part of the country (altitude 959 m, Lat, Long: 8.89932, 39.91726);

- and Shewarobit hospital is located in Amhara Regional State in the northern part of the country
- 138 (altitude 1268 m; Lat, Long: 10.01734, 39.91253).





140

142

143 Sample collection

144

Blood samples diagnosed positive for *P. vivax* (pure or mixed *P. vivax/P. falciparum*) by qPCR

146 from patients seen at health facilities were included to determine their Duffy status. The sample

- size was calculated based on the proportion of Duffy-negative (20%) cases previously reported
- in Ethiopia (23).

¹⁴¹ Figure 1. A map of the study sites with malaria risk stratification background, Ethiopia.

149

Malaria diagnosis by Rapid Diagnostic Tests (RDT) and microscopy 150 Finger prick blood samples were collected from self-reported febrile patients seeking malaria 151 diagnosis at a participating health centre. The malaria laboratory diagnosis was carried out for 152 each suspected malaria patient using RDT and microscopy. SD BIOLINE Malaria Ag Pf/Pv 153 (05FK80) RDT was used for the detection of HRP-II (Histidine-rich protein II) specific for P. 154 falciparum and Plasmodium lactate dehydrogenase (pLDH) specific for P. vivax. Five 155 microliters (5µl) of sample were obtained for the test and the result was interpreted after 15 156 157 minutes (up to 30 minutes) according to the manufacturer's guidelines. Thick and thin blood films (stained with 10% Giemsa staining solution - pH 7.2 - for 10 minutes) 158 were prepared from finger-prick blood samples. Parasite densities were determined on thick 159 160 films by expert malaria microscopists for both sexual and asexual stages of the parasites, considering a minimum of 200 WBCs, the reported number of parasites per microliter of blood, 161 assuming a total white blood cell count of 8000/µL. P. vivax sexual stages/gametocytes 162 quantification was performed on the blood film with P. vivax (pure) and a mixed species (P. 163 vivax/P. falciparum). Parasitemia was then classified as low (<1000 parasites per microliter of 164 blood), intermediate (1000-4999 parasites per microliter of blood) and high (≥5000 parasites per 165 microliter of blood) (24). Slides were declared negative after examination of at least 100 high-166 power microscope fields (25). Blood film slides were re-examined and quantified by WHO 167 168 certified malaria microscopists. Patients who were positive for *P. vivax* (pure) and mixed *P.* vivax/P. falciparum infection by both RDT and microscopy were included in the study. Venous 169 blood samples were collected and spotted onto Whatman[™] 903 Protein Saver Card, US (Dried 170 171 Blood Spot, DBS), for molecular analysis of the Duffy genotypes.

172 DNA extraction and molecular diagnosis of *Plasmodium* species

- 173 Genomic DNA (human and parasite) was extracted from a 6 mm diameter spot of a DBS sample
- and eluted in 100µl of TE Buffer (Tris-EDTA) using the QIAamp DNA Extraction Kit (Cat.No:
- 175 79216, Lot: 172018338, Germany) according to the manufacturer's instructions for the
- 176 molecular identification of malaria parasites and Duffy genotypes. The extracted DNA was
- 177 stored at -20° C for further use.
- 178 Primers previously designed to target the mitochondrial species-specific *cytochrome b (cytb)*
- gene were used for the detection and identification of *P. vivax* and *P. falciparum* (*Table 1*).
- 180 Given the multiple copies of the mitochondria, this assay allows the detection of low density
- 181 *Plasmodium* infections in malaria pre-elimination settings (26).
- 182

183 Table 1. Species-specific primers used for the detection and the species identification of P.

Species	Forward or Reverse	Primer
P vivar	Forward	5'- TGCTACAGGTGCATCTCTTGTATTC -3'
1	Reverse	5'- ATTTGTCCCCAAGGTAAAACG -3'
P falcinarum	Forward	5'- ATGGATATCTGGATTGATTTTATTATGA -3'
1 . <i>Juicipar</i> um	Reverse	5'- TCCTCCACATATCCAAATTACTGC -3'

184 vivax and P. falciparum.

The PCR amplifications were carried out using 10 μ L of Advanced Mix Sybgreen (2x) (Catalog # 1725271, Bio-Rad laboratories Inc. United State), 4 μ L of water, 0.5 μ L of each primer, and 5 µL of DNA template with the final volume of 20 μ L in a Bio-Rad CFX96TM Real-Time PCR detection system.

190

191 Molecular Identification of the Duffy genotypes

- 192 Molecular identification of the Duffy genotype was based on a novel sequence-specific PCR
- 193 primers (Amplification Refractory Mutation System, ARMS) that allows amplifications of the
- 194 GATA-1 transcription factor-binding site of the DARC gene promoter only when the target allele
- 195 (TCT for Duffy-positive and CCT for Duffy-negative genotypes) is detected in the sample.
- 196 Different sets of primers were designed and tested using Duffy-positive and Duffy-negative
- 197 DNA controls which were validated by PCR and Sanger sequencing (see S1 Appendix A) (27) to
- detect the Duffy genotype by qPCR. The forward primers contain a nucleotide mismatch at the 3'

end (T for Duffy-positive and C for Duffy-negative genotypes) in addition to a mismatch base

- near to the SNP at the 3' end (C for Duffy-positive and A for Duffy-negative genotypes), to
- 201 avoid false-amplification and prevent binding to non-complementary sequence and terminate
- amplification. The reverse primer are the same (*Table 2*). All Duffy negative samples found by
- 203 PCR ARMS have been confirmed by Sanger sequencing.
- 204

205 Table 2: AMRS PCR primers used for the detection of Duffy-positive and -negative genotypes.

Duffy	Forward or	
genotype	Reverse	Primer
positive	Forward	5'- CCCTCATTAGTCCTTGGCTCTCAT -3'
1	Reverse	5'- CACCCTGTGCAGACAGTTCC -3'
negative	Forward	5'- CCCTCATTAGTCCTTGGCTCTAAC -3'
0 1 •	Reverse	5'- CACCCTGTGCAGACAGTTCC -3'

Briefly, polymorphisms in the GATA-1 were detected in two separate real-time PCR reactions. 207 Real-time PCR reactions were performed with 10 µL of ssAdvanced mix sybgreen 2x, 10µM of 208 primers and 5 µL of DNA extract, and amplified on the CFX96 PCR instrument (Bio-Rad, 209 Marnes-la-Coquette, France). PCR amplification was carried out under the following conditions: 210 heating at 98 °C for 3 min, followed by 35 cycles of heating at 95 °C for 20 s, and of 211 annealing/extension at 62 °C for 30 s and a final extension step at 72°C for 10 min. After 212 completion of the amplification reaction, a melting curve (65-90°C) was generated to detect non-213 specific PCR amplification. For each run, homozygous (TCT/TCT), heterozygous (TCT/CCT) 214 Duffy-positive, and homozygous Duffy-negative (CCT/CCT) samples were included as positive 215 controls and a no template (water) as negative control (see S1 Appendix B). 216

217

218 Statistical analyses

Data were analysed using Statistical Package for Social Sciences (SPSS, version 25). Chisquared, or Fisher's exact tests were used for frequency data (expressed as percentages).
Associations between Duffy genotypes and different variables were assessed using Fisher's exact
test. Two-sided p-values less than 0.05 were considered as statistically significant.

223

224 Ethical statement

Ethical approval was obtained from Aklilu Lema Institute of Pathobiology Institutional Review Board (IRB) (Ref No: ALIPB IRB/34/2013/20), Addis Ababa University, Addis Ababa, Ethiopia. An official letter was sent to the study sites and the study was initiated after obtaining permission from the respective health facilities. Written informed consent and/or assent was obtained from all study participants, using the local language where appropriate.

230

231 **Results**

- 232 *Characteristics of study participants.* A total of 361 PCR-confirmed *P. vivax* (mono or mixed)
- infected samples were included for the molecular analysis of Duffy status. Among them, 126

(34.9%) were female, the mean age was 25 years old (ranging from 1-80 years old), 108 (29.9%)

had no occupation, and 152 (42.1%) participants live in rural areas (*Table 3*).

237	Table 3. Sociodemographic ch	haracteristics of study	participants in	Ethiopia (n=361)
-----	------------------------------	-------------------------	-----------------	------------------

Variables	Category	Number	Percent (%)
Caralan	Female	126	34.9
Gender	Male	235	65.1
	≤14	40	11.1
Age stratification	15-24	135	37.4
in years	25-34	122	33.8
	≥35	64	17.7
	Amhara	106	29.4
	Anuak	13	3.6
	Somale	6	1.7
Ethnia	Oromo	76	21.1
Eulific	Afar	52	14.4
	Tigre	11	3.0
	Welayita	30	8.3
	Gamo	37	10.2

	Sidama	11	3.0
	Hadiya	3	0.8
	Nuer	16	4.4
	Arbaminch	74	20.5
	Dubti	68	18.8
Study Sites	Gambella	74	20.5
	Metehara	75	20.8
	Shewarobit	70	19.4

238

Based on Duffy genotyping, 345 (95.6%) of the *P. vivax* patients were Duffy-positives (272

240 (78.8%) were heterozygous and 73 (21.2%) were homozygous) and 16 (4.4%) were Duffy-

241 negatives.



244 Figure 2. Pie chart of Duffy status of study participants, Ethiopia (n=361)

246 Distribution of the Duffy genotypes by study sites, study participants, ethnicity, gender, and

247 age.

Amongst the 361 samples tested, 73 (20.2%) were TCT/TCT, 272 (75.4%) were TCT/CCT and 248 249 16 (4.4%) were CCT/CCT. The Duffy-negative patients (CCT/CCT genotype) from Arbaminch, Gambella, Metehara and Shewa robit was 2.7%, 8.1%, 4.0%, and 7.1%, respectively (*Figure 3*). 250 251 No Duffy-negatives were detected from Dubti. The highest proportion of Duffy-negatives was in Gambella (8.1%, 6/74) and the lowest in Arbaminch (2.7%, 2/74). There was no significant 252 association between Duffy genotype and study site (p=0.12). The highest proportion of Duffy-253 negatives was observed in the Nuer ethnic group (12.5%, 2/16) followed by the Agnuwak group 254 (7.7%, 1/13). No Duffy-negatives was identified among the Somale, Afar, Tigre, Welayita and 255 256 Hadiya ethnic groups. No significant association was found between Duffy genotype and ethnic 257 group (p=0.50). About 5.5% (13/235) male and 2.4% (3/126) female participants were Duffynegatives, with no significant association between Duffy genotype and gender (p=0.16). From 258 different age stratification(22), the lowest proportion of Duffy-negatives was identified from the 259 age groups ≤ 14 (2.5%, 1/40) and 25-34 (2.5%, 3/122), while the highest proportion was 260 identified from the age group \geq 35 (7.8%, 5/64), no significant association between Duffy 261 genotype and age groups (p=0.337). (*Table 4*). Similarly, among the Duffy-positive 262 participants, the relative proportions of heterozygous and homozygous were not associated with 263 either study site (p=0.47), ethnic group (p=0.47) or gender (p=0.17) (*Table 5*). 264 265





Figure 3. Map showing the distribution of the Duffy genotypes at five different malaria
 endemic sites in Ethiopia.

270

271 Table 4. Analysis of Duffy status by study sites (altitude), study participants ethnicity and

272 gender (n=361)

		Dı	iffy Status		Chi-	
	Variables	Positive	Negative	Total	Sauare	p-value
		n (%)	n (%)	I otai	Square	
Study	Arbaminch(1200 m)	72 (97.3)	2 (2.7)	74	7.284	0.12

sites	Dubti (379 m)	68 (100)	0	68		
(altitude)	Gambella (447 m)	68 (91.9)	6 (8.1)	74	-	
	Metehara (959 m)	72 (96.0)	3 (4.0)	75	-	
	Shewarobit(1268 m)	65 (92.9)	5 (7.1)	70	-	
	Amhara	100 (94.3)	6 (5.7)	106		
	Agnuwak	12 (92.3)	1 (7.7)	13	-	
	Somale	6 (100	0	6	-	
Fthnic of	Oromo	71 (93.4)	5 (6.6)	76	-	
Study	Afar	52 (100)	0	52	-	
narticina	Tigre	11 (100)	0	11	9.313	0.50
nts	welayita	30 (100)	0	30	-	
	Gamo	35 (94.6)	2 (5.4	37	-	
	Sidama	11 (100)	0 (0)	11	-	
	Hadiya	3 (100%)	0	3	-	
	Nuer	14 (87.5)	2 (12.5)	16	-	
Gender	Female	123 (97.6)	3(2.4)	126	1.923	0.16
	Male	222 (94.5)	13(5.5)	235		
	≤14	39(97.5%)	1 (2.5%)	40		
Age in	15-24	128(94.8%)	7 (5.2%)	135	3 381	0 337
years	25-34	119(97.5%)	3 (2.5%)	122	2.201	
	≥35	59 (92.2%)	5 (7.8%)	64	-	

274 Table 5. Analysis of heterozygous and homozygous Duffy positive patients with study site

275 (altitude), ethnicity, and gender (n = 312)

		Duffy Positive				
Varia	ables	Homozygous	Heterozygous	Total	Chi- Square	p-value
		n (%)	n (%)	1000	~ 1	
	Arbaminch	20 (27.8)	52 (72.2)	72		
Study Sites	Dubti	12 (17.6)	56 (82.4)	68		
(altitudo)	Gambella	16 (23.5)	52 (76.5)	68	3.546	0.47
(annuut)	Metehara	12 (16.7)	60 (83.3)	72		
	Shewarobit	13 (20.0)	52 (80.0)	65		
	Amhara	20 (20.0)	80 (80.0)	100		
	Agnuwak	4 (33.3)	8 (66.7)	12		
-	Somale	0 (0.0)	6 (100)	6		
-	Oromo	13 (18.3)	58 (81.7)	71		
Ethnicity of	Afar	10 (19.2)	42 (80.8)	52		
study	Tigre	2 (18.2)	9 (81.8)	11	9.608	0.47
participants	welayita	7 (23.3)	23 (76.7)	30		
-	Gamo	10 (28.6)	25 (71.4)	35		
-	Sidama	5 (45.5)	6 (54.5)	11		
-	Hadiya	0 (0)	3 (100)	3		
-	Nuer	2 (14.3)	12 (85.7)	14		
Gender	Female	31 (25.2)	92 (74.8)	123	1.874	0.17

	Male	42 (18.9)	180 (81.1)	222		
	≤14	4 (10.3%)	35 (89.7%)	39		
Age in	15-24	31 (24.2%)	97 (75.8%)	128	3 801	0 284
years	25-34	24 (20.2%)	95 (79.8%)	119	5.001	0.201
	≥35	14 (23.7%)	45 (76.3%)	59	-	

276

277

278 Distribution of the Duffy genotype by P. vivax infections.

For the 16 *P. vivax* infections in Duffy negatives, 12 (75%) were mono-infection and four (25%)

280 were mixed *P. vivax/P. falciparum* infections. For the 345 *P. vivax* infections in Duffy positives,

281 312 (90%) were mono-infections and 33 (~10%) were mixed *P. vivax/P. falciparum* infections.

282 The proportion of mixed *P. vivax/P. falciparum* infections was two-fold higher in Duffy-negative

than in Duffy positive individuals (p=0.047), despite small samples for the Duffy negatives

(*Table 6*). Of the 73 homozygous Duffy-positives, 68 (93.2%) were pure *P. vivax* infections and

5 (6.8%) were mixed *P. vivax/P. falciparum* infections, slightly lower than that observed in

heterozygous Duffy-positives of which 244 (78.2%) were pure *P. vivax* infections and 28

287 (10.3%) were mixed *P. vivax/P. falciparum* infections (p=0.37) (*Table 6*).

288

Table 6. Analysis of P. vivax pure and mixed P. vivax/P. falciparum infections with Duffy

290 *genotype (n=361)*.

Va	ariables	P. vivax infections Chi-		Chi-	Р-	
		Pure n (%)	Mixed n (%)	Total	Square	value
Duffy	positive	312 (90.4)	33 (9.6)	345	3.96	0.047

genotype	negative	12 (75)	4 (25)	16		
	Total	324 (89.8)	37 (10.2)	361		
Duffy	homozygous	68 (93.2)	5 (6.8)	73	0.79	0.37
Positive	heterozygous	244 (89.7)	28 (10.3)	272		
	Total	312 (90.4)	33 (9.6)	345		

291

292 Asexual and sexual parasitemia comparison by Duffy groups

293 Of the samples with an asexual stage density of $<1,000 \text{ p/}\mu\text{L}$ and ranging from 1,000 to 4,999

 $p/\mu L$, 9/60 (15.0%) and 7/131 (5.3%) were obtained from Duffy-negative individuals,

respectively. Interestingly, no Duffy-negatives were detected with as exual parasite density \geq 5000

 $p/\mu L$ but only Duffy positive patients (n=170; *Table 7*). The mean asexual parasite density in

homozygous and heterozygous Duffy-positives was 12,165 p/µl (IQR25-75: 1,640-24,234 p/µl)

and 11,655 p/ μ l (IQR25-75: 1,676-14,065 p/ μ l), respectively, significantly higher than that in

299 Duffy-negatives (1,227p/µl; IQR25-75: 539-1,732p/µl) (*p*<0.001; *Figure 4*).

300 Of the samples with a sexual gametocytemia of $<1,000 \text{ p/}\mu\text{L}, 8/180 (4.4\%)$ were detected in

301 Duffy-negative individuals (*Table 7*). The other eight *P. vivax* infections in Duffy negatives were

detected with no gametocytes. By contrast, 172/180 (95.6%) of the Duffy-positives were

detected with sexual gametocytemia of $<1,000 \text{ p/}\mu\text{L}, 31$ were detected with gametocytemia of

1,000-4999 p/ μ L, and 4 with gametocytemia of \geq 5,000 p/ μ L.

305

306 Table 7. Association of Duffy status with asexual parasite density (n=361)

	Duffy Status			Chi-	-
Variables	Positive	Negative	Total	Square	p-value



Key: *Fy+/+; homozygous Duffy-positive, Fy+/-; Heterozygous Duffy-positive, Fy-/-; Duffy-negative*

- 314
- Figure 4: Box plot showing the distribution of asexual parasite density among identified Duffy
- 316 *status*.
- 317

318

319 **Discussion**

320 We report here the association between 361 pure *P. vivax* and mixed *P. vivax/P. falciparum*

- 321 infections collected from five eco-epidemiological study sites in Ethiopia and the Duffy
- 322 genotype of the patients. We assessed malaria infection by qPCR and polymorphisms in the
- 323 GATA-1 promoter affecting Duffy status by a novel ARMS-PCR approach. Here, we observed
- that the proportion of Duffy-negative (4.4%) among *P.vivax* infected patients was lower than
- previous studies conducted in different countries; Madagascar (9.3%)(27), different parts of
- Ethiopia (10.5–11.9%)(16), and Sudan 17.9% (9), but relatively higher than study reports such as
- Ethiopia 2.9%(22), south-eastern Iran 1.3%(28), Brazilian Amazon 0.6%(18). Duffy blood

328 groups remain highly polymorphic between different populations (29). Historically, individuals

with the Duffy-negative phenotype were thought to be resistant to *P. vivax* infection (18,19,30–

330 32), but recent reports have shown *P. vivax* infection in Duffy-negative individuals (20,33-37) in

331 many parts of Africa.

This study identified 4.4% (16/361) P. vivax infections in Duffy-negative patients. This is 332 different from Central or West Africa, where the Duffy-negative genotype is much more 333 334 common and almost all *P. vivax* infections occur among Duffy-negative individuals (36,38,39). despite relatively low number of *P. vivax* cases compared to East Africa. Several hypotheses 335 have been put forward to explain the change in the pattern of infection in Duffy-negative 336 337 individuals. One is a change in the host susceptibility, which in turn may drastically affect the distribution of P. vivax (9) and another is that P. vivax may have evolved to adapt to a wider 338 range of hosts, environments, and highly competent transmission vectors in Africa (33). 339 Alternatively, *P. vivax* parasites may have developed alternative mechanisms to bind and invade 340

reticulocytes as other host cell receptors have been shown to be involved in erythrocyte invasion(40).

Polymorphisms in Duffy blood group among different ethnic groups may contribute to 343 the changing epidemiology of *vivax* malaria in Africa (41). The Ethiopian population has a very 344 heterogeneous ethnic composition. Eleven different ethnic groups were included in this study 345 346 and the proportion of Duffy-negative and Duffy-positive varied between ethnic groups and study sites. A high proportion of Duffy-negative samples were observed among the Nuer followed by 347 the Agnuwak ethnic groups, but no Duffy-negative was identified among the Somale, Afar, 348 349 Tigre, Welayita and Hadiya ethnic groups. Other studies have also showed variation of Duffy genotype between ethnic groups. For example, in Sudan the Duffy-negative phenotype was 350 identified in 83% of Shagia and 77% of Manasir tribes (42); in Mauritania 54% of Moors were 351 352 Duffy-positives while only 2% of black ethnic groups were Duffy-positives (41); in Colombia Duffy genotypes were significantly associated with ethnicity (43). These findings suggest that 353 ethnic groups may be genetically distinct, resulting in different levels of susceptibility to P. vivax 354 infection, in addition to different hypothesis such as P. vivax trains with a new capacity for 355 erythrocyte invasion(27), or use several receptor-ligand interactions to tightly bind erythrocytes 356 357 in the absence of a Duffy receptor(21).

Duffy-negatives with pure *P. vivax* and mixed *P. vivax/P. falciparum* infections was identified in the current study. The proportion of mixed *P. vivax/P. falciparum* infections in Duffy-negative was 25% in the present study, which was similar with the findings from Nigeria (25%)(45), and Cameroon (25%)(44), while it was lower than the study conducted in Madagascar (26.7%)(46), and Democratic Republic of the Congo (64%)(38). The results provide

evidence that Duffy-negative individuals can be infected by pure *P. vivax* alone or together with*P. falciparum.*

365	The mean as exual parasite density among Duffy-negatives (CCT/CCT) was 1,227 p/ μ l,
366	around tenfold lower compared to homozygous Duffy-positives (TCT/TCT; 12,165 p/ μ l) and
367	heterozygous Duffy-positive (TCT/CCT; 11,655 p/ μ l). Several prior studies have shown that <i>P</i> .
368	vivax infections observed in Duffy-negatives have a significantly lower parasitemia than in
369	Duffy-positive infections and are asymptomatic (13)(16). The low parasite densities found in
370	Duffy-negative malaria patients may indicate that <i>P. vivax</i> uses an alternative pathway to invade
371	Duffy-negative reticulocytes, which can be much less efficient than the classical pathway
372	involving the interaction between PvDBP and DARC (22). Alternatively, it has been
373	hypothesized that the reticulocytes of Duffy-negative individuals may express the DARC protein
374	in a transient and weak manner, thereby mediating a low invasion capacity (16). Among the 16
375	Duffy negative samples detected in this study, half were detected with low-level gametocytes.
376	The presence of gametocytes among Duffy negatives may further imply that these infections
377	have the potential contributing to onward transmission.
378	To conclude, this study reports heterogeneous proportions of Duffy-negative individuals
379	among P. vivax malaria patients across Ethiopia, confirms that Duffy-negativity does not provide
380	complete protection against <i>P. vivax</i> infection, and these infections are often associated with low
381	parasitemia, which may represent hidden reservoirs that can contribute to transmission.

382 Therefore, the development of *P. vivax*-specific elimination strategies, including alternative

antimalarial vaccines other than a Duffy-binding protein-based vaccine, should be facilitated by

a better understanding of the relationship between Duffy-negativity and the invasion mechanismsof *P. vivax*.

386

387 Abbreviations

- 388 ALIPB: Aklilu Lema Institute of Pathobiology; *DARC*: Duffy antigen receptor for chemokines;
- 389 DBP: Duffy Binding Protein; DBS: Dried Blood Spots; DNA: Deoxyribonucleic Acid; EPHI:
- Ethiopian Public Health Institute; HRP: Histidine-rich protein; IRB: Institutional Review Board;
- 391 MoE: Ministry of Education; NSP: National Strategic Plan; pLDH: *Plasmodium* lactate
- dehydrogenase; *Pv/Pf: Plasmodium vivax and Plasmodium falciparum;* RDT: Rapid Diagnostic
- 393 Tests; RT PCR: Real Time Polymerase Chain Reaction; SNP: Single Nucleotide Polymorphism;
- 394 SOP: Standard Operating Procedures; SPSS: Statistical Package for Social Sciences; WBC:
- 395 White Blood Cells; WHO: World Health Organization

396

397 Acknowledgements

- 398 This work was supported by i) SIDA project, ii) Human, Heredity and Health in Africa
- 399 (H3Africa) [H3A-18-002]. H3Africa is managed by the Science for Africa Foundation (SFA
- 400 Foundation) in partnership with Wellcome, NIH and AfSHG and iii) the Institute Pasteur, Paris,
- 401 the University of Strasbourg, and the French Government (Agence Nationale de la Recherche;
- 402 ANR- 18-CE15-0026, ANR-21-CE35-0006 and the Laboratoire d'Excellence 'French
- 403 Parasitology Alliance for Health Care', ANR-11-15 LABX-0024-PARAFRAP), and iv) EPHI.
- 404 We would like to thank all the individuals who contributed technically to this study: the
- laboratory staff at the study sites, the staff at ALIPB (parasitology department), the staff at the
- 406 Institute of Parasitology and Tropical Diseases, University of Strasbourg (Cécile Doderer-Lang),
- 407 and the statisticians (Dereje Dilu, Abriham Keraleme and Chalie). We must express our sincere

- 408 gratitude to all the regional health offices and the study sites for their cooperation. Last but not
- least, our sincere thanks go to all the participants who took part in this study.
- 410

411 Authors Contribution

- 412 AA: Abnet Abebe, IB: Isabelle Bouyssou, SM: Solenne Mabilotte, SD: Sisay Dugassa, AA2:
- 413 Ashenafi Assefa, JJ: Jonathan Juliano, DM: Didier Menard, LG: Lemu Golassa
- 414
- 415 Conceptualization and Design: AA, LG
- 416 Drafting Proposal: AA
- 417 Revision: AA, LG, DM, SD, AA2, JJ
- 418 Data Collection: AA, LG, AA2, SD
- 419 Laboratory analysis: AA, IB, SM, DM, LG
- 420 Validation: AA, LG, DM, SD, AA2, JJ
- 421 Writing manuscript draft: AA
- 422 Writing manuscript- review & editing: AA, LG, DM, SD, AA2, JJ

423

- 425
- 426
- 427
- 428
- 429

430 **References**

431

432	1	World Health	Organization ((WHO)	World Malaria	Report 2022
432	1.	wonu neann	Organization (WII OJ.		x c p o t 2022.

- 433 https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022.
- 434 2. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, et al.
- 435 Vivax malaria: A major cause of morbidity in early infancy. Clinical Infectious Diseases.

436 2009;48(12):1704–12.

- 437 3. Kevin Baird J. Evidence and implications of mortality associated with acute plasmodium
 438 vivax malaria. Clinical Microbiology Reviews. 2013;26(1):36–57.
- 4. Moreira CM, Abo-Shehada M, Price RN, Drakeley CJ. A systematic review of submicroscopic Plasmodium vivax infection. Malaria Journal. 2015;14(1):1–10.
- 441 5. Abebe A, Golassa L, Janies DA, Yewhalaw D, Lo E. Gene Polymorphisms Among
- 442 Plasmodium vivax Geographical Isolates and the Potential as New Biomarkers for
- Gametocyte Detection. 2022;11(January):1–12.
- 6. Asok Caudhurit, Julia Polyakovat, Valerea Zbrzenat, Kennett William, Subhash Gulati
- 445 Pogo OA. Cloning of glycoprotein D cDNA, which encodes the major subunit of the
- 446 Duffy blood group system and the receptor for the Plasmodium vivax malaria parasite.
- 447 Proc Natl Acad Sci USA. 1993;90:10793–10797.
- 448 7. Tournamille C, Colin Y, Cartron JP, Le Van Kim C. "Disruption of a GATA motif in the
- 449 Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals."
- 450 Nat Genet. 1995;10(2):224–8.
- 451 8. Howes RE, Patil AP, Piel FB, Nyangiri OA, Kabaria CW, Gething PW, et al. The global
 452 distribution of the Duffy blood group. Nat Commun. 2011;2(4):266.

453 9. Musab MA, Albsheer KP, Safaa A, Mohammed E, Eiman G, Salma MA E al. D	vistribution
--	--------------

- 454 of Duffy Phenotypes among Plasmodium vivax Infections in Sudan. Genes. 2019;10:417.
- 455 10. Popovici J, Roesch C, Rougeron V. The enigmatic mechanismsby which Plasmodium
- 456 vivax infects Duffy-negative individuals. PLoS Pathog. 2020;16(2):e1008258.
- 457 11. Kepple D, Pestana K, Tomida J, Abebe A, Golassa L, Lo E. Alternative invasion
- 458 mechanisms and host immune response to Plasmodium vivax malaria: Trends and future
- directions. Microorganisms. 2021;9(1):1–17.
- 460 12. Daniels G. The molecular genetics of blood group polymorphism. Transplant
- 461 Immunology. 2005;14(3-4 SPEC. ISS.):143–53.
- 462 13. Gunalan K, Niangaly A, Thera MA, Doumbo OK, Miller LH. Plasmodium vivax
- 463 Infections of Duffy-Negative Erythrocytes: Historically Undetected or a Recent
- Adaptation? Trends in Parasitology. 2018;34(5):420–9. Available from:
- 465 http://dx.doi.org/10.1016/j.pt.2018.02.006
- 466 14. Yazdanbakhsh K, Rios M, Storry JR, Kosower N, Parasol N, Chaudhuri A, et A.
- 467 Molecular mechanisms that lead to reduced expression of duffy antigens. Transfusion.
 468 2000;40(3):310–20.
- 469 15. Schmid P, Ravenell KR, Sheldon SL FW. DARC alleles and Duffy phenotypes in African
 470 Americans. Transfusion. 2012;52:1260–7.
- 16. Loa E, Gianluca Russob, Pestanaa K, Kepplea D, Abageroc BR, Ghyslaine Bruna, et A.
- 472 Contrasting epidemiology and genetic variation of Plasmodium vivax infecting Duffy-
- 473 negative individuals across Africa. International Journal of Infectious Diseases.
- 474 2021;108:63–71.
- 17. Lo E, Yewhalaw D, Zhong D, Zemene E, Degefa T, Tushune K. Molecular epidemiology

476	of Plasmodium vivax and Plasmodium falciparum malaria among Duffy-positive and
477	Duffy-negative populations in Ethiopia. Malaria Journal. 2015;14(84).

- 18. Carlos EC, Luiz CM, Álvaro AR, D'Almeida C, Vanja SC, Yuri G, et A. Duffy blood
- group gene polymorphisms among malaria vivax patients in four areas of the Brazilian
- 480 Amazon region. Malaria Journal. 2007;6:167.
- 19. Roesch C, Id JP, Bin S, Run V, Kim S, Rakotomalala E, et al. Genetic diversity in two
 Plasmodium vivax protein ligands for reticulocyte invasion. 2018;1–17.
- 483 20. Mendes C, Dias F, Figueiredo J, Mora VG, Cano J, de Sousa B, et A. Duffy Negative
- 484 Antigen Is No Longer a Barrier to Plasmodium vivax Molecular Evidences from the
- 485 African West Coast (Angola and Equatorial Guinea). PLoS Negl Trop Dis.
- 486 2011;5(6):e1192.
- 487 21. Wilairatana P, Masangkay FR, Kotepui KU, Milanez GDJ, Kotepui M. Prevalence and

488 risk of Plasmodium vivax infection among Duffy - negative individuals : a systematic

review and meta - analysis. Scientific Reports. 2022;1–13. Available from:

490 https://doi.org/10.1038/s41598-022-07711-5

- 491 22. Abate A, Bouyssou I, Mabilotte S, Lang CD, Dembele L, Menard D, et al. Vivax malaria
- in Duffy negative patients shows invariably low asexual parasitaemia : implication
- towards malaria control in Ethiopia. Malaria Journal. 2022;1–10. Available from:
- 494 https://doi.org/10.1186/s12936-022-04250-2
- 495 23. Tamirat Gebru Woldearegai, Peter G. Kremsner, Jürgen F. J. Kun BM. Plasmodium vivax
- 496 malaria in Duffy-negative individuals from Ethiopia. Transactions of The Royal Society
- 497 of Tropical Medicine and Hygiene. 2013;107(5):328–31.
- 498 24. Debash H, Bisetegn H, Ebrahim H, Feleke DG, Gedefie A, Tilahun M, et al. Prevalence

- 499 and associated risk factors of malaria among febrile under-five children visiting health
- 500 facilities in Ziquala district, Northeast Ethiopia: A multicenter cross-sectional study. PLoS
- 501 ONE. 2022;17(10 October):1–13. Available from:
- 502 http://dx.doi.org/10.1371/journal.pone.0276899
- 503 25. Nicholas D, Julie S, Aung P, Hadjar S, Armedy H, Enny K, et A. Gametocyte Dynamics
- and the Role of Drugs in Reducing the Transmission Potential of Plasmodium vivax. JID.
- 505 2013;208:802–12.
- 506 26. Canier L, Khim N, Kim S, Sluydts V, Heng S, Dourng D, et al. An innovative tool for
- 507 moving malaria PCR detection of parasite reservoir into the field. Malaria Journal.

508 2013;12(1):1–12.

- 509 27. Ménard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A, et A.
- 510 Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy
- 511 people. Proc Natl Acad Sci USA. 2010;107(13):5967–71.
- 512 28. Miri-moghaddam E, Bameri Z, Mohamadi M. Duffy blood group genotypes among
- 513 malaria Plasmodium vivax patients of Baoulch population in southeastern Iran. Asian
- 514 Pacific Journal of Tropical Medicine. 2014;7(3):206–7. Available from:
- 515 http://dx.doi.org/10.1016/S1995-7645(14)60021-3
- 51629.Ewa Ł, Nowak I, Czerwinski M, Wa K. Duffy blood group system the frequency of Du
- 517 ff y antigen polymorphisms and novel mutations in the Polish population.
- 518 2019;(December 2018).
- 519 30. Guerra CA, Howes RE, Patil AP, Gething PW, van Boeckel TP, Temperley WH, et al.
- 520 The international limits and population at risk of Plasmodium vivax transmission in 2009.
- 521 PLoS Neglected Tropical Diseases. 2010;4(8).

522	31.	Miller LH, Mason SJ, Clyde DF MM. The resistance factor to Plasmodium vivax in
523		blacks: the Duffy-blood-group genotype, FyFy. N Engl J Med. 1976;295:302-4.
524	32.	Rondônia D, Brasileira AO, Cavasini CE, José F, Pereira T, Ribeiro WL, et al. Duffy
525		blood group genotypes among malaria patients in Rondônia, Western Brazilian Amazon
526		Genótipos do sistema sanguíneo Duffy em pacientes maláricos. 2001;34(6):591–5.
527	33.	Abdelraheem MH, Albsheer MMA, Mohamed HS, Amin M, Hamid MMA. Transmission
528		of Plasmodium vivax in Duffy-negative individuals in central Sudan. Transactions of the
529		Royal Society of Tropical Medicine and Hygiene. 2016;110(4):258-60.
530	34.	Zimmerman PA. Plasmodium vivax infection in Duffy-Negative People in Africa. Am J
531		Trop Med Hyg. 2017;97.
532	35.	Dongho GBD, Gunalan K, L'Episcopia M, Paganotti GM, Menegon M, Sangong RE, et
533		al. Plasmodium vivax Infections Detected in a Large Number of Febrile Duffy-Negative
534		Africans in Dschang, Cameroon. American Journal of Tropical Medicine and Hygiene.
535		2021;104(3):987–92.
536	36.	Oboh MA, Badiane AS, Ntadom G, Ndiaye YD, Diongue K, Diallo MA, et al. Molecular
537		identification of Plasmodium species responsible for malaria reveals Plasmodium vivax
538		isolates in Duffy negative individuals from southwestern Nigeria. Malaria Journal.
539		2018;17(1):1-12. Available from: https://doi.org/10.1186/s12936-018-2588-7
540	37.	Ryan JR, Stoute JA, Amon J, Dunton RF, Mtalib R, Koros J, et al. Evidence for
541		transmission of Plasmodium vivax among a Duffy antigen negative population in Western
542		Kenya. American Journal of Tropical Medicine and Hygiene. 2006;75(4):575-81.
543	38.	Brazeau NF, Whitesell AN, Doctor SM, Keeler C, Mwandagalirwa MK, Tshefu AK, et al.
544		Plasmodium vivax infections in duffy-negative individuals in the democratic republic of

545		the Congo. American Journal of Tropical Medicine and Hygiene. 2018;99(5):1128–33.
546	39.	Poirier P, Doderer-Lang C, Atchade PS, Lemoine JP, De L'Isle MLC, Abou-Bacar A, et
547		al. The hide and seek of Plasmodium vivax in West Africa: Report from a large-scale
548		study in Beninese asymptomatic subjects. Malaria Journal. 2016;15(1):1-9.
549	40.	Gruszczyk J, Kanjee U, Chan LJ, Menant S, Malleret B, Lim NTY, et al. Transferrin
550		receptor 1 is a reticulocyte-specific receptor for Plasmodium vivax. Science.
551		2018;359(6371):48–55.
552	41.	Wurtz N, Mint Lekweiry K, Bogreau H, Pradines B, Rogier C, Ould Mohamed Salem
553		Boukhary A, et al. Vivax malaria in Mauritania includes infection of a Duffy-negative
554		individual. Malaria Journal. 2011;10:1-8.
555	42.	Kempi A, Knap O, Drozd A, Kaczmarczyk M, Parafiniuk M. Analysis for genotyping
556		Duffy blood group in inhabitants of Sudan, the Fourth Cataract of the Nile. 2012;1-6.
557	43.	Gonzalez L, Veg J, Ramirez Jose L, Bedoya G C-F. Relationship between Duffy blood
558		groups genotypes and malaria infection in different ethnic groups of Choco- Colombia.
559		Colomb Med [online] 2012, vol43, n3, pp189-195. 2012;43(3):189-95.
560	44.	Gaelle H, Mbenda N, Das A. Molecular Evidence of Plasmodium vivax Mono and Mixed
561		Malaria Parasite Infections in Duffy-Negative Native Cameroonians. 2014;9(8):1–9.
562	45.	Oboh MA, Singh US, Ndiaye D, Badiane AS, Ali NA, Bharti PK, et al. Presence of
563		additional Plasmodium vivax malaria in Duffy negative individuals from Southwestern
564		Nigeria. Malaria Journal. 2020;1–8. Available from: https://doi.org/10.1186/s12936-020-
565		03301-w
566	46.	Ménard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A, et al.
567		Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy

568	people. Proceedings of the National Academy of Sciences of the United States of
569	America. 2010;107(13):5967-71.
570	
571	
572	
573	Supporting information
574	
575	Appendix A: Figures summarizing Sanger sequencing data
576 577	Appendix B: Figures summarizing AMRS PCR-based allelic discrimination amplification curves in a control samples validated by PCR/Sanger sequencing
578	